Revalesio Corporation
13
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
46.2%
6 terminated/withdrawn out of 13 trials
53.8%
-32.7% vs industry average
0%
0 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis
Role: lead
Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy
Role: lead
Study of Electro-kinetically Modified Water for the Treatment of Pain Associated With Endometriosis
Role: lead
Effect of RNS60 on the Late Phase Asthmatic Response to Allergen Challenge
Role: lead
Pilot Study of RNS60 in Allergen-induced Bronchoconstriction
Role: lead
Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis
Role: lead
Systemic Bioactivity of Inhaled Nebulized RNS60
Role: lead
Study of RNS60 on Pain and Function After Knee Anterior Cruciate Ligament Surgery
Role: lead
Study of RNS60 on Pain and Function After Hip Labral Repair
Role: lead
Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma
Role: lead
Feasibility Study to Evaluate the Safety of Topically Applied Revera in Subjects With Venous Leg Ulcers
Role: lead
Safety Study of Nebulized RNS60 to Treat Asthma.
Role: lead
Safety and Tolerability of RNS60 Given by IV to Healthy Subjects
Role: lead
All 13 trials loaded